­
­
­
­

Inventi Rapid - Urology & Nephrology
(Formerly Inventi Rapid/Impact: Kidney)

Patent Watch

  • METHODS AND COMPOSITIONS FOR DIAGNOSIS OF IGA-AND IGM-MEDIATED KIDNEY DISEASES

    The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schonlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders.

  • METHODS FOR CHARACTERIZING KIDNEY FUNCTION

    Embodiments of the invention relate generally to methods of characterizing kidney function. In particular, several embodiments quantify kidney-associated marker RNA isolated from vesicles contained in patient urine samples. In some embodiments, the quantified RNA from urine vesicles is compared to a normal population and in some embodiments is compared to the patient to evaluate kidney function over time.

  • METHODS OF PREDICTING PREDISPOSITION TO OR RISK OF KIDNEY DISEASE

    Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T. brucei. The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and/or a deletion of N388 and Y389 to the subject.

  • KIDNEY PROGNOSTIC ASSAY

    The invention provides a method of predicting subjects at risk of loss of kidney function and/or identifying subjects at greater risk of loss of kidney function, and/or identifying subjects at risk of kidney failure/end stage kidney disease, the method comprising detecting an amount of free light chains (FLC) in a sample from the subject, wherein a higher amount of FLC is associated with increased risk of loss of kidney function and/or increased risk of renal failure/end stage kidney disease. A further aspect of the invention provides a method of monitoring renal impairment, comprising detecting an amount of free light chains (FLC) in a sample from a subject having renal impairment and comparing the amount of FLC in the sample with an Total FLC amount of FLC detected in a sample previously obtained from the subject, wherein an increase in the amount FLC detected, compared to the previous sample, indicates an increase in the risk of loss of renal function in the subject, and a decrease in the amount of FLC indicates a decrease in the risk of loss of renal function in the subject.

  • METHODS FOR TREATMENT OR PROPHYLAXIS OF KIDNEY OR LIVER DYSFUNCTION

    Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs.

  • METHOD FOR DETERMINING STAGE OF CHRONIC KIDNEY DISEASE, DEVICE THEREFOR AND METHOD FOR OPERATING THE SAME

    This invention provides a method or device for determining the stage of chronic kidney disease. The present invention relates to a method for determining a stage of chronic kidney disease in a subject suffering from kidney disease, the method comprising the steps of: (A-1) measuring the content of at least one marker selected from the group consisting of markers (1) to (16) in a specimen from the subject, (B-1) determining the stage indicated by each marker by comparing the content of the at least one marker in the specimen from the subject, which has been measured in step (A-1), with a reference content range determined in each stage, and (C-1) determining that when each marker indicates the same stage, which has been determined in step (A-1), the chronic kidney disease in the subject is in that stage.

  • DIAGNOSTIC METHOD FOR DETECTING ACUTE KIDNEY INJURY USING HEAT SHOCK PROTEIN 72 AS A SENSITIVE BIOMARKER

    The invention relates to a reliable, easy-to-implement non-invasive diagnostic method for detecting early acute kidney injury by measuring the concentration of a biomarker in urine samples, said biomarker being selected from heat shock proteins of the 70 KDa family. More specifically, the invention relates to the identification of heat shock protein 72, whereby said biomarker is identified by means of ELISA and Western blot or by means of the level of RNAm using real-time RT-PCR. The invention helps to solve the current problem that exists in medicine whereby it is not possible to detect acute renal failure in the early stages or the severity of the renal damage in order to treat the patient in a timely manner with an effective therapy.

  • FORMULATION FOR ALLEVIATION OF KIDNEY STONE AND GALLSTONE SYMPTOMS

    A nutraceutical formula and food-based medicinal composition is provided comprising homeopathic ingredients in combination with traditional herbal and nutraceutical ingredients for relieving the symptoms associated with presence or formation of kidney stones and gallstones. The formulation includes ingredients balanced in a synergistic manner to elicit complementary effects which both reduce the symptoms of kidney stones and gallstones and provide the potential to eliminate their occurrence in the body and prevent future recurrence. Methods of making and using core medicinal formulations and food-based compositions are also described.

  • Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease

    The invention comprises use of a therapeutically effective amount of the compound of the formula below for preparation of a medicament for treating polycystic kidney diseases (PKD) in a mammal, such as human or feline (e.g., Persian cat).Formula (I). Also provided are the above compound and compositions comprising it for treating PKD. ##STR00001##

  • METHODS AND COMPOSITIONS FOR MANAGING CARDIOVASCULAR DISEASE ASSOCIATED WITH CHRONIC KIDNEY DISEASE

    Methods of treating cardiovascular disease in patients predisposed to or afflicted with kidney disease, particularly chronic kidney disease, are described. In such methods, therapeutically effective amounts of chloroquine-based compounds, for example, hydroxychloroquine, are administered to prevent or otherwise ameliorate arthrosclerosis and other cardiovascular diseases.

  • Biomarkers for Predicting Kidney and Glomerular Pathologies

    Biomarkers for determining a kidney and glomerular pathologies and methods of using the same are described.

  • Non-Lithotripsic Kidney-Stone Therapy

    One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.

  • Confinement of Kidney Stone Fragments During Lithotripsy

    The present invention improves significantly the success rate of lithotripsy and reduces the risk of tissue damage, by injecting a temporary plug in front, and optionally behind a concretion (for extracorporeal lithotripsy) or behind a concretion (for intracorporeal lithotripsy). One aspect of the present invention relates to injecting an inverse thermosensitive polymer solution into a lumen, thereby preventing the migration of a concretion, or its fragments, upon extracorporeal or intracorporeal lithotripsy.

  • METHODS FOR TREATMENT OR PROPHYLAXIS OF KIDNEY OR LIVER DYSFUNCTION

    Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs.

  • METHOD FOR EARLY PROGNOSIS OF KIDNEY DISEASE

    Certain embodiments of the present invention relate to methods for detecting kidney disease, in particular early stage kidney disease.

  • Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus

    Methods for predicting a propensity for heart or kidney failure in a diabetic or pre-diabetic individual by determining the amount and/or molecular weight of islet amyloid polypeptide present in a sample from the individual are provided.

  • METHOD OF DETERMINING KIDNEY TRANSPLANTATION TOLERANCE

    The present invention relates to a method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers. The present invention also relates to a kit comprising reagents for detecting the levels of the biomarkers. The present invention also relates to a sensor for detecting the expression levels of a plurality of genes that can be used to determine an individual's transplantation tolerance.

  • METHODS FOR TREATING A KIDNEY INJURY

    Provided herein are methods of treating a kidney injury in a patient, comprising administering to the patient hematopoietic stem cells (HSCs) in an amount effective to treat the kidney injury. In some embodiments, administration of the HSCs is delayed, such that the HSCs are not administered immediately after the kidney injury. In certain aspects, the HSCs are administered to the patient during the beginning of the repair phase of the kidney. Further embodiments and aspects of the invention, including related methods and compositions for use therein, are described herein.

  • COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY

    The invention provides compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury, resulting for example from increased intra-abdominal pressure, using phosphodiesterase inhibitors, more particularly phosphodiesterase type inhibitors, or pharmaceutically acceptable salts or solvates thereof.

  • MARKERS FOR ACUTE KIDNEY INJURY AND USES THEREOF

    The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury.

  • Methods of Treating Acute Kidney Injury Using Mesenchymal Stem Cells

    The invention relates to methods of treating acute kidney injury (AKI) in a patient by administering a therapeutic amount of mesenchymal stem cells (MSC) to a patient in need thereof. Administration of MSCs ameliorates AKI in the patient when administered up to at least 48 hours following kidney injury or decline in kidney function.

  • Methods and Compositions for the Prevention and Treatment of Kidney Disease

    The invention provides compositions for preventing or treating kidney disease and improving kidney function comprising at least two ingredients selected from the group consisting of antioxidants and mitochondrial cofactors in amounts sufficient for preventing or treating kidney disease or for improving kidney function and methods for preventing and treating kidney disease or improving kidney function comprising administering such compositions to an animal susceptible to or suffering from kidney disease or impaired kidney function. In a preferred embodiment, the composition is admixed with one or more food ingredients to produce a food composition useful for preventing or treating kidney disease and improving kidney function, particularly in senior animals.

  • METHODS FOR DIAGNOSING AND ASSESSING KIDNEY DISEASE

    The technology relates in part to methods for identifying the presence of kidney disease, determining the level of kidney disease, or the progression of kidney disease, in a subject that has or has not been diagnosed with diabetes. The technology further relates to methods for determining the targets for therapy for kidney disease, the efficacy of a treatment for kidney disease, and methods for determining the toxicity of a therapeutic in a subject with kidney disease. The technology relates in part to methods for identifying the presence of kidney disease, determining the level of kidney disease, or the progression of kidney disease, in a subject that has or has not been diagnosed with diabetes. The technology further relates to methods for determining the targets for therapy for kidney disease, the efficacy of a treatment for kidney disease, and methods for determining the toxicity of a therapeutic in a subject with kidney disease.

  • Methods of Detecting Kidney-Associated Diseases or Conditions

    The disclosure provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of kidney associated diseases or conditions. The disclosure also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of kidney-associated diseases or conditions.

  • BIOMARKERS FOR ACUTE KIDNEY INJURY

    Disclosed is an animal model that can be used, among other things, to generate biomarkers for the prognosis and/or diagnosis of acute kidney injury, more specifically sepsis-induced acute kidney injury. Disclosed are three such biomarkers. The disclosure specifically relates to human chitinase 3-like protein 1 for use as a biomarker.

  • USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS

    Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.

  • NOVEL HERBAL COMPOSITION FOR THE TREATMENT OF KIDNEY STONE AND OTHER URINARY TRACT DISORDERS

    Discloses a novel synergistic herbal composition comprising combination of therapeutically effective amount of Vrun bhavit, Kadalikshar, Apamargkshar, Yavkshar and optionally Gomutrakshar along with pharmaceutical acceptable additives, useful for the treatment of kidney stone and other urinary disorders like inflammation and urinary stent related problems.

  • PREDICTION OF ACUTE KIDNEY INJURY FROM A POST-SURGICAL METABOLIC BLOOD PANEL

    Systems and methods are provided for predicting the likelihood of acute kidney injury. An input interface is configured to receive a plurality of features derived from the results of a post-surgical metabolic blood panel and either a pre-surgical metabolic blood panel or a perisurgical metabolic blood panel. A predictive model is configured to calculate a parameter representing a likelihood of acute kidney injury from the plurality of features. A user interface is configured to provide the calculated parameter to a user in a human comprehensible form.

  • Detection and Treatment of Polycystic Kidney Disease

    Compositions useful for examining the PKD1 gene are provided. In addition, methods for detecting mutations of the PKD1 gene, which can be associated with autosomal dominant polycystic kidney disease in humans, are provided. Methods for diagnosing a mutant PKD1 gene sequence in a subject also are provided, as are methods of treating a subject having a PKD1-associated disorder.

  • METHODS FOR DETECTING OR PREDICTING KIDNEY DISEASE

    Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen.

  • METHODS AND COMPOSITIONS FOR INHIBITING CYCLOPHILIN D FOR THE TREATMENT AND PREVENTION OF OBESITY AND KIDNEY INDICATIONS

    Methods and compositions for modulating cyclophilin D, e.g., at least one cyclophilin D biological activity, are provided. Modulation of cyclophilin D is useful in preventing or treating obesity, an overweight condition, or in accommodating a desire to lose weight as well as being useful in treating a variety of kidney diseases.